Collaborative to Speed Clinical Research and Reduce Costs


Press releases may be edited for formatting or style | May 24, 2011
* Clinical Research, Pharmaceutical, and HIT Organizations: Bayer HealthCare Pharmaceuticals, Inc., F. Hoffman-La Roche, Ltd., Johnson and Johnson, Merck & Co., Inc., Oracle, Pfizer, Inc., and Quintiles
* Project Management: Booz & Company and Quintiles Consulting

The guiding principle behind PACeR is the benefit to patients. Ensuring robust patient privacy and consent protections is paramount. Incorporating patient advocacy groups in PACeR's participation and governance ensures that their role and benefits are a top priority. PACeR will continue to ensure that all solutions deployed will allow patients to decide how their personal medical information will be used.

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

HANYS' President Daniel Sisto said, "The rapid change we see in the health care system is also occurring in medical research, and the PACeR collaborative is at the forefront of revolutionizing how medical research is conducted and how the benefits of this research are shared. The PACeR collaborative has proven that bringing together diverse stakeholders is an effective approach to finding ways to improve clinical trials using electronic data. HANYS looks forward to continuing this important work, which promises to help speed new, effective treatments to patients, while improving the efficiency of the entire clinical trial process."

David A. Krusch, M.D., Chief Medical Information Officer, University of Rochester Medical Center, and Chair of the PACeR Governing Group, commented, "PACeR brings tremendous opportunities to enhance the entire clinical trials research process; from study design, patient identification, to the actual conduct of the trial itself. Most importantly, PACeR not only facilitates clinical research, but in doing so it brings new and novel therapeutic opportunities to patients who may never have had such options if not for this new and exciting technology. One can think of PACeR as introducing a new era in the development of dramatic increases in quality of care."

PACeR's Next Phase: Building Infrastructure for Enhanced Clinical Research

PACeR is currently soliciting funding for Phase 2, to begin demonstration projects to develop the infrastructure needed to advance more efficient and effective clinical research. Consistent with PACeR's objectives, the projects will all involve multiple academic medical centers to demonstrate the capability to provide protocol modeling input across many institutions. Pending funding, projects under consideration include:

You Must Be Logged In To Post A Comment